Nuvectis Pharma, Inc.
NVCT
$8.76
-$0.04-0.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.30% | -32.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.27% | 18.18% | |||
| Operating Income | 2.27% | -18.18% | |||
| Income Before Tax | 1.98% | -17.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.98% | -17.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.98% | -17.81% | |||
| EBIT | 2.27% | -18.18% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 27.58% | -46.90% | |||
| Normalized Basic EPS | 3.99% | -10.79% | |||
| EPS Diluted | 27.58% | -46.90% | |||
| Normalized Diluted EPS | 3.99% | -10.79% | |||
| Average Basic Shares Outstanding | 2.10% | 6.33% | |||
| Average Diluted Shares Outstanding | 2.10% | 6.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||